Primary navigation

    Sirturo

    Drug - Sirturo™ [Janssen]

    October 2013

    Therapeutic Area - Antituberculosis agents

    Approval criteria

    • Patient is 18 years of age or older AND
    • Patient has a diagnosis of pulmonary multi-drug resistant tuberculosis AND
    • Prescriber has reported the case to the Minnesota Department of Health

    Quantity limit

    Treatment is limited to 24 weeks of therapy.

    Background information

    SIRTURO™ is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO™ for use when an effective treatment regimen cannot otherwise be provided. SIRTURO™ is not indicated for the treatment of latent, extra-pulmonary or drug-sensitive tuberculosis or for the treatment of infections caused by non-tuberculous mycobacteria.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top